PDF(Pubmed)
Abstract：
In recent years, with the deepening understanding of the gut microbiota, it has been recognized to play a significant role in the development and progression of diseases. Particularly in gastrointestinal tumors, the gut microbiota influences tumor growth by dysbiosis, release of bacterial toxins, and modulation of host signaling pathways and immune status. Immune checkpoint inhibitors (ICIs) have greatly improved cancer treatment efficacy by enhancing immune cell responses. Current clinical and preclinical studies have demonstrated that the gut microbiota and its metabolites can enhance the effectiveness of immunotherapy. Furthermore, certain gut microbiota can serve as biomarkers for predicting immunotherapy responses. Interventions targeting the gut microbiota for the treatment of gastrointestinal diseases, especially colorectal cancer (CRC), include fecal microbiota transplantation, probiotics, prebiotics, engineered bacteria, and dietary interventions. These approaches not only improve the efficacy of ICIs but also hold promise for enhancing immunotherapy outcomes. In this review, we primarily discuss the role of the gut microbiota and its metabolites in tumors, host immunity, and immunotherapy.
摘要：
近年来,随着人们对肠道微生物群认识的加深,它已被认为在疾病的发展和进展中起着重要作用。特别是在胃肠道肿瘤中，肠道菌群通过菌群失调影响肿瘤生长，释放细菌毒素，以及调节宿主信号通路和免疫状态。免疫检查点抑制剂（ICIs）通过增强免疫细胞反应大大提高了癌症治疗功效。目前的临床和临床前研究表明，肠道菌群及其代谢产物可以增强免疫治疗的有效性。此外，某些肠道微生物群可以作为预测免疫治疗反应的生物标志物。针对肠道微生物群的干预措施，用于治疗胃肠道疾病，尤其是结直肠癌（CRC），包括粪便微生物移植，益生菌，益生元,工程细菌，和饮食干预。这些方法不仅提高了ICIs的疗效，而且有望增强免疫治疗结果。在这次审查中,我们主要讨论肠道微生物群及其代谢产物在肿瘤中的作用，宿主免疫,和免疫疗法。
